The natural history of nephrocalcinosis in premature infants treated with loop diuretics - PubMed (original) (raw)

Clinical Trial

The natural history of nephrocalcinosis in premature infants treated with loop diuretics

J C Pope 4th et al. J Urol. 1996 Aug.

Abstract

Purpose: We investigated the natural history of nephrocalcinosis in premature infants treated with furosemide and attempted to identify factors to predict infants most at risk.

Materials and methods: We evaluated 13 preterm infants in this longitudinal pilot study. During hospitalization and while receiving a loop diuretic nephrocalcinosis developed in each patient. Patients were divided into groups based on resolution (6) and nonresolution (7) according to spontaneous resolution of nephrocalcinosis at any point during followup. The 2 groups were compared to each other and to a control group.

Results: Mean followup after discontinuation of furosemide in the resolution versus nonresolution groups was 10.3 and 7.7 months, respectively. Between the 2 groups there was no significant difference in average gestational age, birth weight, number of days hospitalized or on furosemide, or total furosemide dose. Mean calcium-to-creatinine ratio while receiving furosemide at the time nephrocalcinosis developed was 0.38 in the resolution group but 2.23 in the nonresolution group (p < 0.005). Initial calcium-to-creatinine ratio in age matched infants who did not have nephrocalcinosis was 0.4. Frank renal stones developed in 2 of the 7 patients without resolution and 0 of the 6 with resolution. When nephrocalcinosis resolved, it was at a mean of 5.2 months following discontinuation of the diuretic.

Conclusions: Early data indicate that nephrocalcinosis resolves in approximately 50% of premature infants 5 to 6 months after discontinuation of furosemide. The only factor that appears to be predictive of the infants who will have resolution is the calcium-to-creatinine ratio when nephrocalcinosis is diagnosed. In patients without resolution this ratio is much higher than in age adjusted normal controls, while in those with resolution it appears normal for age.

PubMed Disclaimer

Cited by

Drug-Induced Urolithiasis in Pediatric Patients.
Sighinolfi MC, Eissa A, Bevilacqua L, Zoeir A, Ciarlariello S, Morini E, Puliatti S, Durante V, Ceccarelli PL, Micali S, Bianchi G, Rocco B. Sighinolfi MC, et al. Paediatr Drugs. 2019 Oct;21(5):323-344. doi: 10.1007/s40272-019-00355-5. Paediatr Drugs. 2019. PMID: 31541411 Review.
Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review.
Jackson W, Taylor G, Selewski D, Smith PB, Tolleson-Rinehart S, Laughon MM. Jackson W, et al. Matern Health Neonatol Perinatol. 2018 Nov 19;4:23. doi: 10.1186/s40748-018-0092-2. eCollection 2018. Matern Health Neonatol Perinatol. 2018. PMID: 30473868 Free PMC article. Review.
Nephrocalcinosis in a preterm infant.
Fox L, Rogerson S. Fox L, et al. Australas J Ultrasound Med. 2009 Aug;12(3):42-43. doi: 10.1002/j.2205-0140.2009.tb00060.x. Epub 2015 Dec 31. Australas J Ultrasound Med. 2009. PMID: 28191062 Free PMC article.
The long-term complications of the inherited tubulopathies: an adult perspective.
Khosravi M, Walsh SB. Khosravi M, et al. Pediatr Nephrol. 2015 Mar;30(3):385-95. doi: 10.1007/s00467-014-2779-6. Epub 2014 Feb 25. Pediatr Nephrol. 2015. PMID: 24566812 Review.
Clinical pharmacology of furosemide in neonates: a review.
Pacifici GM. Pacifici GM. Pharmaceuticals (Basel). 2013 Sep 5;6(9):1094-129. doi: 10.3390/ph6091094. Pharmaceuticals (Basel). 2013. PMID: 24276421 Free PMC article.

The natural history of nephrocalcinosis in premature infants treated with loop diuretics - PubMed (original) (raw)